Synmosa Biopharma Corp.   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Taipei Taiwan (1980)
Status: Left NME R&D (2015)

Organization Overview

First Clinical Trial
2005
NCT00190034
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Synmosa Biopharma Corp.

Active Ingredients

Drugs in Phase 4 Trials (1)

acetylcysteine (mucomyst) (1 trial)

Drugs in Phase 3 Trials (1)

elobixibat (1 trial)

Drugs in Phase 2 Trials (2)

azelastine (astelin) (1 trial)

fluticasone (cutivate) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 4)

Cardiovascular Diseases (Phase 4)

Renal Insufficiency (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 4